Novo Nordisk® ernational Operations and GLP-1 Added reported therapy area sales and growth DKK billion 6 4 2 0 -2 North America Operations International Operations 7% -3% 29% 6% 37% 12% 27% 10% 8% 2% -22% 4% Growth at CER 4% 8% -2% -4 -6 Total1 Insulin GLP-1 Obesity Biopharm World; NAO: North America Operations
Share
Download PDF file
